All In Biotech

Drug Trial Radar · NCT04356495

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France)

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

412

Actual

Start

Jul 29, 2020

Primary completion

Oct 8, 2021

Study completion Oct 22, 2021

Sponsor

Lead sponsor
University Hospital, BordeauxAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Bordeaux
First posted
Apr 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In adults with COVID-19 without criteria for hospitalization or oxygen therapy but with risk factors for aggravation, early treatment may avoid hospitalization, indication for oxygen therapy or death. No treatment is currently validated for this indication.

Conditions

  • Corona Virus Infection
  • Sars-CoV2

Interventions

  • VitaminsDietary supplement

    2 tablets daily from the first day (day 0) to day 9

  • TelmisartanDrug

    1 tablet daily from the first day (day 0) to day 9

  • CiclesonideDrug

    2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9

  • interferon β-1bDrug

    A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pilot Phase: Proportion of participants who had a Grade 3 or 4 adverse eventTime frame: From inclusion (day0) to day 14
  2. Efficacy phase: DeathTime frame: From inclusion (day0) to day 14
  3. Efficacy phase: oxygen therapyTime frame: From inclusion (day0) to day 14
  4. Efficacy phase: hospitalizationTime frame: From inclusion (day0) to day 14

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Bordeaux university Hospital

    Bordeaux, France

  • CHU de Dijon-Bourgogne

    Dijon, France

  • CHU de Montpellier

    Montpellier, France

  • CHRU de Nancy

    Nancy, France

  • Groupe hospitalier Paris Saint Joseph

    Paris, France

  • CNGE

    Paris, France

  • CHU de Toulouse

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.